爱豆传媒

Investors

Your browser does not support iframes.

爱豆传媒 Release

December 5, 2024

鈥淟EQEMBI庐鈥� (Lecanemab) Approved for the Treatment of Early Alzheimer鈥檚 Disease in Mexico
November 29, 2024

Eisai Announces Completion of Cancellation of Treasury Shares
Cancellation of treasury shares pursuant to the provisions of Article 178 of the Companies Act
November 28, 2024

鈥淟EQEMBI庐鈥� (Lecanemab) for the Treatment of Alzheimer鈥檚 Disease Launched in South Korea
November 26, 2024

EISAI SIGNS RESEARCH COLLABORATION AGREEMENT WITH THE NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY TO INITIATE APOLIPOPROTEIN E GENETIC TESTING IN THE 鈥淎D-DMT REGISTRY鈥� IN JAPAN
November 20, 2024

ROZEBALAMIN庐 FOR INJECTION 25 MG (MECOBALAMIN) FOR AMYOTROPHIC LATERAL SCLEROSIS LAUNCHED IN JAPAN

Latest Financial Reports

Consolidated Financial Report for Second Quarter Financial Results for the Fiscal Year Ending March 31, 2025

November 8, 2024

Consolidated Financial Report
November 8, 2024

Reference Data
November 8, 2024

Financial Results Presentation

Latest Financial Reports

Financial Information

Latest Presentations

Electronic Public Notice

No corporate bonds have been issued at present.